Phase IIb, multicenter, randomized, double-blind, placebo-controlled study of verinurad and allopurinol in patients with chronic kidney disease and hyperuricemia. SAPPHIRE
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA AB
- Phase: II
- Execution start: 20/11/2019
- End of execution: 30/08/2021
- PI: MANUEL EDUARDO MUÑOZ TORRES